Scott Cohen, DO
Gastroenterology · Mount Laurel, NJNPI 1497843288
Payments from drug & device makers
Across 361 payments — averaging $16.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Johnson & Johnson$1K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$569
- Takeda Pharmaceuticals U.S.A., Inc.$464
- Nestle Healthcare Nutrition Inc.$349
- Ardelyx, Inc.$215
- plus $2K from 30 others
What the payments were for
- Food & beverage$5,72196%
- Education$2284%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 106 | $1,629 |
| Johnson & Johnson | 57 | $1,001 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 36 | $569 |
| Takeda Pharmaceuticals U.S.A., Inc. | 31 | $464 |
| Nestle Healthcare Nutrition Inc. | 21 | $349 |
| Ardelyx, Inc. | 13 | $215 |
| Sanofi | 10 | $164 |
| Bristol Myers Squibb | 9 | $139 |
| Merck | 10 | $136 |
| Medtronic | 1 | $126 |
| Gilead | 8 | $122 |
| Intercept Pharmaceuticals, Inc. | 8 | $116 |
| Phathom Pharmaceuticals, Inc. | 6 | $113 |
| Pharmacosmos Therapeutics Inc. | 2 | $93 |
| Ipsen Biopharmaceuticals, Inc | 4 | $84 |
| Lilly USA, LLC | 3 | $59 |
| Daiichi Sankyo Inc. | 3 | $50 |
| Regeneron Healthcare Solutions, Inc. | 3 | $48 |
| Redhill Biopharma Inc. | 3 | $44 |
| Concordia Pharmaceuticals Inc. | 3 | $43 |
| QOL Medical, LLC | 3 | $41 |
| Laborie Medical Technologies Corp. | 1 | $38 |
| Madrigal Pharmaceuticals | 2 | $35 |
| Evoke Pharma, Inc. | 2 | $33 |
| Intra-sana Laboratories | 2 | $29 |
| Alfasigma USA, Inc. | 2 | $28 |
| Shire North American Group Inc | 2 | $26 |
| Romark Laboratories, LC | 2 | $23 |
| Exact Sciences | 1 | $23 |
| Vivus LLC | 1 | $22 |
| Olympus America Inc. | 1 | $21 |
| Aimmune Therapeutics, Inc. | 1 | $20 |
| Pfizer | 1 | $16 |
| Celltrion USA Inc. | 1 | $15 |
| Ironwood Pharmaceuticals, Inc | 1 | $11 |
| Micro-tech Endoscopy USA, Inc. | 1 | $10 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,950 in reported general payments places this provider in the 70th percentile of 701 gastroenterology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 32 | $819,987 |
| CreonLipase/Protease/Amylase | 43 | $100,981 |
| Dupixent PenDupilumab | 11 | $81,334 |
| IbsrelaTenapanor Hcl | 23 | $50,618 |
| LinzessLinaclotide | 47 | $38,622 |
| XifaxanRifaximin | 11 | $33,294 |
| Dexlansoprazole DrDexlansoprazole | 58 | $26,007 |
| Mesalamine | 39 | $23,329 |
| VoqueznaVonoprazan Fumarate | 20 | $16,127 |
| ViberziEluxadoline | 11 | $15,705 |
| Pantoprazole Sodium | 698 | $8,493 |
| Sucralfate | 76 | $5,287 |
| Ursodiol | 13 | $3,531 |
| Dicyclomine Hcl | 82 | $2,731 |
| CholestyramineCholestyramine (With Sugar) | 20 | $1,839 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $1,001 | $819,98732 claims |
| AbbVieCreon, Linzess, Viberzi | $1,629 | $155,307101 claims |
| Ardelyx, Inc.Ibsrela | $215 | $50,61823 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $569 | $33,29411 claims |
| Phathom Pharmaceuticals, Inc.Voquezna | $113 | $16,12720 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 701 gastroenterology providers in New Jersey.
Other gastroenterology in Mount Laurel
- Adam ElfantMount Laurel$385K
- Anthony InfantolinoMount Laurel$63K
- Kiran RaoSparta$1.3M
- Adekunle AdeotiIrvington$1.2M
- Carl WallachMorristown$766K
- Vinod RustgiNew Brunswick$697K
- Arvind TrindadeNew Brunswick$652K
- Barry KaufmanEgg Harbor Township$595K
- Promila BanerjeeStratford$522K
- Neil NagariaToms River$442K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.